Avanir, Actavis Settle Patent Litigation - Quick Facts

(RTTNews) - Avanir Pharmaceuticals Inc. (AVNR) announced it has entered into a settlement agreement with Actavis South Atlantic LLC and Actavis, Inc. (ACT) to resolve pending patent litigation in response to Actavis' abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA capsules. The agreement grants Actavis the right to begin selling a generic version of NUEDEXTA on July 30, 2026, or earlier under certain circumstances.

Avanir noted that the settlement does not end its ongoing litigation against the other three ANDA filers.